CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Beginning balance	$ (6,036)	$ (27,037)	$ (70,322)
Issuance of common stock and warrants, net of issuance cost			41,343
Issuance of common stock, net of issuance cost		37,625
Issuance of common stock under the Sales Agreement, net	8,236	8,575	4,867
Share-based compensation related to stock options	1,124	1,405	2,264
Share-based compensation related to restricted stock awards	961	970	862
Exercise of warrants	2		472
Reacquisition of equity component of convertible notes		(12,019)
Equity component of convertible notes, net of transaction costs		12,027
Net loss	(14,927)	(27,582)	(6,523)
Ending balance	(10,640)	(6,036)	(27,037)
Common Stock
Beginning balance	$ 46	$ 35	$ 15
Beginning balance (in shares)	45,556,647	34,765,280	14,838,213
Issuance of common stock and warrants, net of issuance cost			$ 18
Issuance of common stock and warrants, net of issuance cost (in shares)			17,604,423
Issuance of common stock, net of issuance cost		$ 9
Issuance of common stock, net of issuance cost (in shares)		8,749,999
Issuance of common stock under the Sales Agreement, net	$ 7	$ 2	$ 1
Issuance of common stock under the Sales Agreement, net (in shares)	7,473,038	1,867,552	1,428,571
Share-based compensation related to restricted stock awards	$ 1		$ 1
Share-based compensation related to restricted stock awards (in shares)	759,482		694,073
Exercise of warrants (in shares)	1,000	173,816	200,000
Ending balance	$ 54	$ 46	$ 35
Ending balance (in shares)	53,790,167	45,556,647	34,765,280
Additional Paid-in Capital
Beginning balance	$ 368,852	$ 320,280	$ 270,492
Issuance of common stock and warrants, net of issuance cost			41,325
Issuance of common stock, net of issuance cost		37,616
Issuance of common stock under the Sales Agreement, net	8,229	8,573	4,866
Share-based compensation related to stock options	1,124	1,405	2,264
Share-based compensation related to restricted stock awards	960	970	861
Exercise of warrants	2		472
Reacquisition of equity component of convertible notes		(12,019)
Equity component of convertible notes, net of transaction costs		12,027
Ending balance	379,167	368,852	320,280
Accumulated Deficit
Beginning balance	(374,934)	(347,352)	(340,829)
Net loss	(14,927)	(27,582)	(6,523)
Ending balance	$ (389,861)	$ (374,934)	$ (347,352)